Search company, investor...
Caribou Biosciences company logo

Caribou Biosciences

cariboubio.com

Founded Year

2011

Stage

IPO | IPO

Total Raised

$158.36M

Date of IPO

7/23/2021

About Caribou Biosciences

Caribou Biosciences (NASDAQ:CRBU) is a developer of cellular engineering and analysis solutions based on CRISPR technologies, which provide enhanced capabilities to therapeutic development, agricultural biotechnology, industrial biotechnology, and basic and applied biological research.

Headquarters Location

2929 7th Street Suite 105

Berkeley, California, 94710,

United States

510-982-6030

Missing: Caribou Biosciences's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Caribou Biosciences's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Research containing Caribou Biosciences

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Caribou Biosciences in 1 CB Insights research brief, most recently on Aug 31, 2021.

Article Thumbnail

Aug 31, 2021

What Is CRISPR?

Expert Collections containing Caribou Biosciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Caribou Biosciences is included in 3 Expert Collections, including Synthetic Biology.

S

Synthetic Biology

305 items

Companies involved in design and development of new biological parts, devices, and systems; as well as the re-design of existing biological systems.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

Caribou Biosciences Patents

Caribou Biosciences has filed 77 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • Biotechnology
  • Genetic engineering
patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/21/2020

1/17/2023

Molecular biology, Social networking services, MPEG-2, Neisseriales, Pathogenic bacteria

Grant

Application Date

9/21/2020

Grant Date

1/17/2023

Title

Related Topics

Molecular biology, Social networking services, MPEG-2, Neisseriales, Pathogenic bacteria

Status

Grant

Latest Caribou Biosciences News

Caribou adds hoofprint, multiple developers ‘herd’ from in ROR1

Jan 27, 2023

Jan. 27, 2023 Caribou Biosciences Inc.’s disclosure last December that it has chosen the target for CB-020, an induced pluripotent stem cell-derived allogeneic CAR-NK cell therapy for solid tumors, added impetus to the growing interest in receptor tyrosine kinase-like orphan receptor 1 (ROR1), where a number of parties are advancing programs.

Caribou Biosciences Frequently Asked Questions (FAQ)

  • When was Caribou Biosciences founded?

    Caribou Biosciences was founded in 2011.

  • Where is Caribou Biosciences's headquarters?

    Caribou Biosciences's headquarters is located at 2929 7th Street, Berkeley.

  • What is Caribou Biosciences's latest funding round?

    Caribou Biosciences's latest funding round is IPO.

  • How much did Caribou Biosciences raise?

    Caribou Biosciences raised a total of $158.36M.

  • Who are the investors of Caribou Biosciences?

    Investors of Caribou Biosciences include Invus Group, Farallon Capital Management, PFM Health Sciences, Monashee Investment Management, Janus Henderson Investors and 28 more.

  • Who are Caribou Biosciences's competitors?

    Competitors of Caribou Biosciences include Synthego.

Compare Caribou Biosciences to Competitors

eGenesis Logo
eGenesis

eGenesis aims to make available safe and reliable Xeno organs, tissues, and cells to patients in need and advance the field of transplantation. It uses gene-editing tools, such as CRISPR, to directly address the key virology and immunology hurdles that have impeded xenotransplantation to date. It develops an initial product for the clinic for kidney transplants, with the longer-term potential of addressing a broader organ recipient population and expanding the applicability of xenotransplantation into other areas such as cell therapy. The company was founded in 2015 and is based in Cambridge, U.K.

Applied StemCell Logo
Applied StemCell

Applied StemCell (ASC) is a biotechnology company providing animal and cell line models as tools for drug discovery and diagnostics. Using its TARGATT gene modification technology, the company makes site-specific Knockin mouse, rat and human cell line models fast and efficient for pharmaceutical and academic community.

S
Somagenics

Somagenics specializes in developing innovative technologies that focus on RNA molecules as therapeutic agents and targets as well as biomarkers. Besides the Real-Seq kit family, the company's detection technology platforms also include miR-ID, a novel circularization-based RT-qPCR method for small RNA detection (specifically isomiRs and isoforms), and res-Q, a method for quantifying fragmented RNA from formaldehyde-fixed, paraffin-embedded histology specimens. SomaGenics's therapeutics platform includes development of targets for its proprietary small short hairpin RNA (sshRNA) in wound healing and anti-viral applications.

ElevateBio Logo
ElevateBio

ElevateBio creates and operates a portfolio of cell and gene therapy companies to develop, manufacture and commercialize life-transforming medicines. The company was founded in 2017 and is based in Cambridge, Massachusetts.

Myllia Biotechnology Logo
Myllia Biotechnology

Myllia Biotechnology is a biotechnology company developing technology that supports the identification of the critical genes and pathways driving certain disease states or impacting the disease phenotype. The company combines CRISPR screening with single-cell RNA sequencing to enable genetic screening for complex phenotypes. Its applications are used in identifying drug targets or elucidating unknown mechanisms of actions of drugs. Myllia Biotechnology, formerly Aelian Biotechnology, was founded in 2018 and is based in Vienna, Austria.

Inscripta Logo
Inscripta

Inscripta develops a gene-editing technology that offers digital genome engineering. It generates low-cost libraries of thousands of designer protein, pathway, or genome variants with trackable mutations and helps researchers to design and track results. The company was founded in 2015 and is based in Boulder, Colorado.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.